CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Aldeyra Therapeutics, Inc. - ALDX CFD

4.89
2%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.04
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024262 %
Charges from full value of position ($-4.61)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00204 %
Charges from full value of position ($0.39)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00204%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 4.99
Open 4.97
1-Year Change 75.62%
Day's Range 4.89 - 5.08
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 13, 2024 4.89 0.08 1.66% 4.81 5.12 4.81
Dec 12, 2024 4.99 -0.29 -5.49% 5.28 5.37 4.95
Dec 11, 2024 5.35 0.12 2.29% 5.23 5.44 5.05
Dec 10, 2024 5.26 0.10 1.94% 5.16 5.42 5.16
Dec 9, 2024 5.20 0.07 1.36% 5.13 5.27 5.03
Dec 6, 2024 5.19 0.25 5.06% 4.94 5.31 4.91
Dec 5, 2024 4.94 0.03 0.61% 4.91 5.19 4.91
Dec 4, 2024 4.93 0.20 4.23% 4.73 4.95 4.66
Dec 3, 2024 4.71 -0.09 -1.87% 4.80 4.88 4.70
Dec 2, 2024 4.79 -0.11 -2.24% 4.90 4.90 4.72
Nov 29, 2024 4.88 -0.06 -1.21% 4.94 5.00 4.82
Nov 27, 2024 4.91 0.12 2.51% 4.79 4.94 4.77
Nov 26, 2024 4.78 -0.14 -2.85% 4.92 4.92 4.72
Nov 25, 2024 4.95 0.10 2.06% 4.85 4.98 4.80
Nov 22, 2024 4.83 0.07 1.47% 4.76 4.98 4.66
Nov 21, 2024 4.79 0.00 0.00% 4.79 4.98 4.64
Nov 20, 2024 4.73 -0.14 -2.87% 4.87 4.98 4.67
Nov 19, 2024 4.92 0.33 7.19% 4.59 4.98 4.59
Nov 18, 2024 4.68 -0.18 -3.70% 4.86 5.10 4.30
Nov 15, 2024 4.18 -0.07 -1.65% 4.25 4.28 4.06

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aldeyra Therapeutics, Inc. Company profile

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 54% to $57.8M. Higher net loss reflects Research and development increase of 98% to $41.4M (expense), General and administrative increase of 15% to $7.7M (expense), General and administrative expenses increase of 8% to $3.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.07.

Industry: Bio Therapeutic Drugs

131 Hartwell Avenue
Suite 320
LEXINGTON
MASSACHUSETTS 02421
US

People also watch

XRP/USD

2.40 Price
-1.870% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01196

ETH/USD

3,845.24 Price
-1.620% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,648.80 Price
-1.210% 1D Chg, %
Long position overnight fee -0.0125%
Short position overnight fee 0.0043%
Overnight fee time 22:00 (UTC)
Spread 0.60

US100

21,741.60 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0020%
Overnight fee time 22:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading